AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENTThe Biopharmaceutical Services Agreement • May 9th, 2012 • Synageva Biopharma Corp • Biological products, (no disgnostic substances)
Contract Type FiledMay 9th, 2012 Company IndustryTHIS AMENDMENT (“Amendment”) effective as of April 27, 2012 (“Effective Date”), is between Synageva BioPharma Corp., a Delaware corporation with a principal office at 128 Spring Street, Suite 520, Lexington MA 02421 (phone: 781-357-9900; fax: 781-357-9901) (“Synageva”) and Cytovance Biologics, Inc. a Delaware corporation having its principal place of business at 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 (“Cytovance”).